IV Glutathione Dosing Regimen for Chemotherapy-Induced Peripheral Neuropathy Prevention

Evidence-Based Dosing by Clinical Indication

The American Society of Clinical Oncology recommends administering 1,500 mg/m² IV over 15 minutes immediately before each chemotherapy infusion for chemotherapy-induced peripheral neuropathy prevention, based on the most consistent evidence from multiple randomized controlled trials 1, 2, 3
This regimen demonstrated significant reduction in grade 3-4 neurotoxicity (0% vs 26%, P=0.01) with oxaliplatin, with a strength of evidence supported by multiple randomized controlled trials 2, 3
Reduced neuropathy incidence from 88% to 17% after 15 weeks with cisplatin (P<0.001), as evidenced by high-quality clinical trials 1, 2
Alternative dosing regimens studied include 2.5 g IV over 15 minutes for cisplatin-based regimens, with some evidence suggesting efficacy 1, 3
A dose of 3 g/m² IV over 20 minutes before cisplatin improved symptom scores (P=0.05), although the strength of evidence is moderate due to limited sample size 2, 3

Administer IV glutathione immediately before chemotherapy infusion (within 15-20 minutes prior) to maximize neuroprotective effects, as recommended by clinical guidelines 1, 2, 3

Glutathione showed no significant advantage for paclitaxel-induced neuropathy (P=0.449), and weekly paclitaxel schedules may actually favor placebo over glutathione (P=0.002), highlighting the need for alternative neuroprotective strategies in taxane-based regimens 1, 3

Baseline and serial assessment of neuropathy using validated scales (NCI-CTC, EORTC-QLQ-CIPN20) is recommended to monitor treatment efficacy and potential toxicities 1, 2, 3

High-dose parenteral glutamine (not glutathione) is contraindicated in critically ill patients with kidney failure based on REDOX trial data, emphasizing the importance of distinguishing between these compounds and considering potential safety risks 4